“Lebrikizumab Dosed Every 8 Weeks As Maintenance Provides Long-Lasting Response in Patients With Moderate-to-Severe Atopic Dermatitis”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s601. https://doi.org/10.25251/14pn6v71.